-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25

Benzinga·03/16/2026 16:17:51
Listen to the news
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $12 to $25.